Another box ticked - slowly but surely moving forward.Not too worried about the SP at the moment - as far as I'm concerned, most stocks on the ASX seem to be underperforming.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%